Zolotovskaya I A, Davydkin I L
Samara State Medical University, Samara, Russia.
Zh Nevrol Psikhiatr Im S S Korsakova. 2020;120(4):65-71. doi: 10.17116/jnevro202012004165.
To evaluate the antiresorptive-cytokine effects of chondroitin sulfate on non-specific lower back pain in patients with knee osteoarthritis (OA).
Using the envelope method, 231 patients were randomized into two groups: group 1 (=116, main) received nonsteroidal anti-inflammatory drugs (NSAIDs) and chondrogard, group 2 (=115, comparison) received only NSAIDs. The 2-month study included 3 visits (V): V - at the beginning of the study, V - after 10 days, V - after 60 days with the assessment of blood parameters: transforming growth factor β1 (TFR β1), interleukin (IL)-1β and IL-6, beta-Crosslaps, bone matrix formation indicator P1NP (n-terminal propeptide procollagen type 1), and determination of the level of deoxypyridinoline (DPID) in the urine.
At the end of the study, there is a significant decrease in all studied cytokines in patients of group 1 compared to group 2, as well as indicators of beta-Crosslaps (<0,001) and DPID (<0,001), which may indicate the presence of its own antiresorptive-cytokine effect in chondroitin sulfate.
评估硫酸软骨素对膝骨关节炎(OA)患者非特异性下背痛的抗吸收细胞因子作用。
采用信封法,将231例患者随机分为两组:第1组(n = 116,主要组)接受非甾体抗炎药(NSAIDs)和chondrogard,第2组(n = 115,对照组)仅接受NSAIDs。为期2个月的研究包括3次访视(V):V1 - 在研究开始时,V2 - 10天后,V3 - 60天后,评估血液参数:转化生长因子β1(TGFβ1)、白细胞介素(IL)-1β和IL-6、β-交联C端肽、骨基质形成指标P1NP(I型前胶原N端前肽),并测定尿中脱氧吡啶啉(DPID)水平。
研究结束时,与第2组相比,第1组患者所有研究的细胞因子以及β-交联C端肽(<0.001)和DPID(<0.001)指标均显著降低,这可能表明硫酸软骨素具有自身的抗吸收细胞因子作用。